---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060486"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:24:44.978900+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tivic Health reports Q1 net loss down 29% YoY; raises $4M in May offering

## Summary
- Q1 revenue $334K (-11% YoY), net loss $1.5M vs $2.1M, operating expenses down 26%.
- Gross margin improved to 50% from 30%; gross profit up 48% to $167K.
- May 13 public offering: 4.71M shares + warrants at $0.85/share, gross $4M, net $3.5M.
- Clinical study with Feinstein Institutes showed ncVNS induced autonomic and neurologic responses equivalent to implanted devices.
- Launched ClearUP 2.0; exclusive distribution deal with top-10 distributor for Walmart, Target, Kroger.

## SEC filing metadata
- accession: 0000950170-24-060486
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017024060486/0000950170-24-060486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017024060486/tivc-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060486
- JSON: https://secwatch.observer/filing/0000950170-24-060486.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060486.txt

## Key facts
- Earnings Releases
  Valion Bio, Inc. reported first quarter 2024 results: revenue $334 thousand.
  - Period: first quarter 2024
  - Revenue: $334 thousand
  - Result: reported results
  source text: Revenue for Q1 2024 was $334 thousand, compared to $376 thousand for Q1 2023, a decrease of $42 thousand, or 11%, due reduced unit sales volume offset by increased selling price.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017024060486/0000950170-24-060486-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.